Survival Benefit Maintained In Long Term Follow-up Of IES With Pfizer's AROMASIN(R) (Exemestane Tablets)
Links shared publicly online about this topic.
- 1,726total visits
Survival Benefit Maintained In Long Term Follow-up Of IES With Pfizer's AROMASIN(R) (Exemestane Tablets)
Pfizer Inc announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three
View full resource at medicalnewstoday.com
Tags: Women's Health, Pfizer
Most Recently Shared on September 24, 2009 at 12:47 pm By:
Survival Benefit Maintained In Long Term Follow-up Of IES With Pfizer's AROMASIN(R) (Exemestane Tablets): Pfizer.. http://bit.ly/xGumL
Advertisement
